Vir Biotechnology, Inc.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signature
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| VIR BIOTECHNOLOGY, INC. | ||
| Date: February 23, 2026 | By: | /s/ Marianne De Backer |
|---|---|---|
| Marianne De Backer, M.Sc., Ph.D., MBA | ||
| Chief Executive Officer and Director | ||
| (Principal Executive Officer) | ||
| Date: February 23, 2026 | By: | /s/ Jason O’Byrne |
| Jason O’Byrne, MBA | ||
| Executive Vice President and Chief Financial Officer | ||
| (Principal Financial Officer) | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marianne De Backer, M.Sc., Ph.D., MBA, Jason O’Byrne, MBA, and Vanina de Verneuil, J.D., and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Marianne De Backer | Chief Executive Officer and Director | February 23, 2026 |
| Marianne De Backer, M.Sc., Ph.D., MBA | (Principal Executive Officer) | |
| /s/ Jason O’Byrne | Executive Vice President and Chief Financial Officer(Principal Financial Officer) | February 23, 2026 |
| Jason O’Byrne, MBA | ||
| /s/ Brent Sabatini | Senior Vice President and Chief Accounting Officer(Principal Accounting Officer) | February 23, 2026 |
| Brent Sabatini, CPA, MBA | ||
| /s/ Vicki Sato | Chairman of the Board of Directors | February 23, 2026 |
| Vicki Sato, Ph.D. | ||
| /s/ Norbert Bischofberger | Director | February 23, 2026 |
| Norbert Bischofberger, Ph.D. | ||
| /s/ Ramy Farid | Director | February 23, 2026 |
| Ramy Farid, Ph.D. | ||
| /s/ Jeffrey S. Hatfield | Director | February 23, 2026 |
| Jeffrey S. Hatfield, MBA | ||
| /s/ Robert More | Director | February 23, 2026 |
| Robert More, MBA | ||
| /s/ Janet Napolitano | Director | February 23, 2026 |
| Janet Napolitano, J.D. | ||
| /s/ Saira Ramasastry | Director | February 23, 2026 |
| Saira Ramasastry, M.S., M.Phil. | ||
| /s/ Elliott Sigal | Director | February 23, 2026 |
| Elliott Sigal, M.D., Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.